Skip to main content
Premium Trial:

Request an Annual Quote

Genentech to Use Horizon's X-MAN Line

NEW YORK (GenomeWeb News) – Roche subsidiary Genentech will use Horizon Discovery's mutant-and-normal cell lines in its oncology drug research programs under a three year agreement, Horizon said today.

The agreement, which expands an ongoing relationship between the companies, will give Genentech access to Horizon's X-MAN cell-line library.

Earlier in 2009, Genentech licensed the rights to use Horizon's GENESIS gene engineering platform to develop genetically defined human cancer models for drug studies.

The relationship between the two companies "has yielded some exciting findings which are being translated into publications that will help others striving to develop targeted cancer agents," Paul Morrill, business development director at Horizon, said in a statement.

Horizon said that Genentech has agreed to pay up-front, milestone and renewal fees, but it did not provide specific details of the financial terms.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.